M
Muhammad Irfan
Researcher at Hayatabad Medical Complex
Publications - 23
Citations - 79
Muhammad Irfan is an academic researcher from Hayatabad Medical Complex. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 3, co-authored 11 publications receiving 24 citations.
Papers
More filters
Journal ArticleDOI
Fear of COVID-19 and workplace phobia among Pakistani doctors: A survey study.
Sadia Malik,Irfan Ullah,Muhammad Irfan,Daniel Kwasi Ahorsu,Chung Ying Lin,Amir H. Pakpour,Amir H. Pakpour,Mark D. Griffiths,Ibad Ur Rehman,Rafia Minhas +9 more
TL;DR: In this paper, the authors examined the associations between fear of the coronavirus disease-2019 and workplace phobia among doctors in Pakistan during the COVID-19 pandemic and found that doctors with severe levels of fear had significantly higher levels of workplace panic anxiety and workplace avoidance behavior.
Book ChapterDOI
Vulnerability of Environmental Resources in Indus Basin after the Development of Irrigation System
TL;DR: A comprehensive review of irrigation system developments in Indus Basin and its implications on environmental resources is presented in this article, where the authors provide a comprehensive analysis of water quality degradation due to addition of fertilizers, pesticides, chemicals, municipal sewage, and industrial effluents.
Journal ArticleDOI
Central Retinal Vein Occlusion in patients with COVID-19 infection: A systematic review.
Irfan Ullah,Aruba Sohail,Mir Umer Farooq Alam Shah,Maman Khurshid,Mufaddal Najmuddin Diwan,Abdul Qadir,Muhammad Irfan +6 more
TL;DR: In this paper, a systematic review summarizes the evidence on patients diagnosed with central retinal vein occlusion (CRVO) secondary to COVID-19 secondary infection, and highlights the importance of identifying CRVO as an important complication of infection.
Journal ArticleDOI
The revival of telemedicine in the age of COVID-19: Benefits and impediments for Pakistan.
Maheera Farooqi,Irfan Ullah,Muhammad Irfan,Anab Rehan Taseer,Talal Almas,Mohammad Mehedi Hasan,Fatima Muhammad Asad Khan,Abdulaziz Alshamlan,Abdulaziz Abdulhadi,Vikneswaran Raj Nagarajan +9 more
Journal ArticleDOI
Treating Postpartum Depression: What Do We Know about Brexanolone?
Muneeza Ali,Alifiya Aamir,Mufaddal Najmuddin Diwan,Hashir Ali Awan,Irfan Ullah,Muhammad Irfan,Domenico De Berardis +6 more
TL;DR: In 2019, the Food and Drug Administration (FDA) approved brexanolone, an exogenous analog of allopregnanolone, as the first ever drug to be specifically indicated for treating patients with postpartum depression.